IN2014DN03155A - - Google Patents

Info

Publication number
IN2014DN03155A
IN2014DN03155A IN3155DEN2014A IN2014DN03155A IN 2014DN03155 A IN2014DN03155 A IN 2014DN03155A IN 3155DEN2014 A IN3155DEN2014 A IN 3155DEN2014A IN 2014DN03155 A IN2014DN03155 A IN 2014DN03155A
Authority
IN
India
Prior art keywords
imidazol
pyrazole
benzo
dichloro
disorders
Prior art date
Application number
Inventor
Kia Sepassi
Michele C Rizzolio
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IN2014DN03155A publication Critical patent/IN2014DN03155A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The meglumine salt of 1 (5 6 dichloro 1H benzo[d]imidazol 2 yl) 1H pyrazole 4 carboxylic acid (compound (1)) and pharmaceutically acceptable formulations thereof are described. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states disorders and conditions mediated by prolyl hydroxylase activity.
IN3155DEN2014 2011-10-25 2012-10-25 IN2014DN03155A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551395P 2011-10-25 2011-10-25
PCT/US2012/061847 WO2013063221A1 (en) 2011-10-25 2012-10-25 Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid

Publications (1)

Publication Number Publication Date
IN2014DN03155A true IN2014DN03155A (en) 2015-05-22

Family

ID=47116519

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3155DEN2014 IN2014DN03155A (en) 2011-10-25 2012-10-25

Country Status (15)

Country Link
US (4) US9273034B2 (en)
EP (3) EP3091009B1 (en)
JP (2) JP6122862B2 (en)
KR (1) KR102087020B1 (en)
CN (2) CN104053439B (en)
AU (2) AU2012328763A1 (en)
BR (1) BR112014009910B1 (en)
CA (1) CA2853455C (en)
CY (1) CY1123426T1 (en)
ES (3) ES2689481T3 (en)
HK (1) HK1202237A1 (en)
HU (1) HUE052128T2 (en)
IN (1) IN2014DN03155A (en)
MX (2) MX344109B (en)
WO (1) WO2013063221A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2294066B9 (en) 2008-04-28 2015-03-11 Janssen Pharmaceutica, N.V. Benzoimidazoles as prolyl hydroxylase inhibitors
CN115403531A (en) 2011-09-14 2022-11-29 润新生物公司 Chemical entities, compositions, and methods as kinase inhibitors
ES2689481T3 (en) * 2011-10-25 2018-11-14 Janssen Pharmaceutica Nv Formulations of 1- (5,6-dichloro-1h-benzo [d] imidazol-2-yl) -1h-pyrazol-4-carboxylic acid meglumine salt
EP2806874B1 (en) 2012-01-25 2017-11-15 Neupharma, Inc. Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
US9688635B2 (en) 2012-09-24 2017-06-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP2916838B1 (en) 2012-11-12 2019-03-13 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN104610153B (en) * 2015-01-19 2017-02-22 沈阳中海生物技术开发有限公司 Ozagrel meglumine salt, as well as composition, preparation method and application thereof
JP7201273B2 (en) 2018-08-07 2023-01-10 メタゴン バイオテック インク． Ammonium salt of 3-(3,5-dibromo-4-hydroxybenzylidene)-5-iodo-1,3-dihydroindol-2-one and use thereof
JP7483748B2 (en) 2019-11-28 2024-05-15 日本農薬株式会社 Benzimidazole compounds or their salts, agricultural and horticultural insecticides and acaricides containing said compounds, and methods of using the same
EP4138825A1 (en) 2020-04-20 2023-03-01 Akebia Therapeutics Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
WO2022251563A1 (en) 2021-05-27 2022-12-01 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1207994B (en) * 1986-01-03 1989-06-01 Therapicon Srl WATER SOLUBLE SALTS OF ANTI-INFLAMMATORY AND ANALGESIC ADAPTITY COMPOUNDS, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS.
ATE83381T1 (en) 1986-10-22 1993-01-15 Schering Corp USE OF RECOMBINATED HUMAN ALPHA INTERFERON IN THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF THE AIDS VIRUS.
DE3824658A1 (en) 1988-07-15 1990-01-18 Schering Ag N-HETARYL IMIDAZOLE DERIVATIVES
US5258362A (en) 1991-06-11 1993-11-02 Abbott Laboratories Renin inhibiting compounds
ATE149485T1 (en) 1993-11-02 1997-03-15 Hoechst Ag SUBSTITUTED HETEROCYCLIC CARBOXYLIC AMIDE ESTERS, THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS
CA2224062C (en) 1995-06-06 2001-09-04 Pfizer Limited Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
PT970095E (en) 1997-03-07 2004-03-31 Metabasis Therapeutics Inc NEW INHIBITORS BENZIMIDAZOLE OF FRUTOSE-1,6-BISPHOSPHATASE
DE19746287A1 (en) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments
NZ504769A (en) 1998-02-27 2005-04-29 Pfizer Prod Inc N-[(substituted five-membered di- or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia
ES2362727T3 (en) 1999-11-22 2011-07-12 Mallinckrodt Inc. PULSIOXIMETER SENSOR WITH A WIDED STRIP.
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
AR038658A1 (en) 2001-06-15 2005-01-26 Novartis Ag DERIVATIVES OF 4-ARIL-2 (1H) QUINAZOLINONA AND 4-ARIL-QUINAZOLINA 2-SUBSTITUTES, A PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A MEDICINAL PRODUCT
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
CN102977016B (en) 2003-06-06 2015-01-14 菲布罗根有限公司 Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin
PT1660492E (en) 2003-07-28 2008-11-13 Janssen Pharmaceutica Nv Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
BRPI0418212A (en) 2003-12-29 2007-04-27 Banyu Pharma Co Ltd a pharmaceutically acceptable compound or salt thereof, a glucokinase activator, and, medicaments for the therapy and / or prevention of diabetes, and obesity
JP4792048B2 (en) 2005-03-02 2011-10-12 ファイブロゲン インコーポレイティッド Thienopyridine compounds and methods of use thereof
AU2006254897A1 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
ES2274712B1 (en) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. NEW IMIDAZOPIRIDINE DERIVATIVES.
JP5202327B2 (en) 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド Quinolone-based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions thereof and uses thereof
ZA200806752B (en) 2006-01-27 2009-10-28 Fibrogen Inc Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (HIF)
AR059733A1 (en) 2006-03-07 2008-04-23 Smithkline Beecham Corp COMPOSITE DERIVED FROM GLYCIN N- REPLACED WITH BICYCLE HETEROAROMATICS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE TO PREPARE A MEDICINAL PRODUCT TO TREAT ANEMIA AND PROCESS FOR PREPARATION
WO2007136990A2 (en) 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl Hydroxylase Inhibitors
KR101130592B1 (en) 2006-06-26 2012-04-02 워너 칠콧 컴퍼니 엘엘씨 Prolyl hydroxylase inhibitors and methods of use
WO2008033739A2 (en) 2006-09-12 2008-03-20 Neurogen Corporation Benzimidazole carboxamide derivatives
DE102006050516A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New pyrazol-3-one compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful e.g. to treat and/or prophylaxis heart-circulation diseases, heart failure, anemia, chronic kidney diseases and renal failure
DE102006050513A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
WO2008082487A2 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
CL2008000065A1 (en) 2007-01-12 2008-09-22 Smithkline Beecham Corp COMPOUNDS DERIVED FROM N-SUBSTITUTED GLYCINE, INHIBITORS OF HIF PROLIL HYDROXYLASES; YOUR PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE ANEMIA.
CL2008000066A1 (en) 2007-01-12 2008-08-01 Smithkline Beecham Corp COMPOUNDS DERIVED FROM (5-HYDROXY-3-OXO-2,3-DIHYDROPIRIDAZINE-4-CARBONYL) GLYCINE, HIFROXYLASE HYDROXYLASE HIF INHIBITORS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE ANEM
WO2008130527A1 (en) 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
US8048894B2 (en) 2007-04-18 2011-11-01 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
US8097620B2 (en) 2007-05-04 2012-01-17 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
WO2009024190A1 (en) * 2007-08-22 2009-02-26 4Sc Ag Indolopyridines as inhibitors of the kinesin spindle protein (eg5 )
DE102007048447A1 (en) 2007-10-10 2009-04-16 Bayer Healthcare Ag New substituted dihydropyrazole-3-thione compounds are hypoxia inducible factor-prolyl-4-hydroxylase inhibitor, useful for preparing medicament to treat and/or prevent e.g. cardiovascular diseases, wound healing and anemia
DE102007049157A1 (en) 2007-10-13 2009-04-16 Bayer Healthcare Ag New substituted 2,3-dihydro-(1,2,3)triazol-4-one compounds are hypoxia inducible factor-prolyl-4-hydroxylase inhibitor, useful for preparing medicament to treat and/or prevent e.g. cardiovascular diseases, inflammatory disease and anemia
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
WO2009086044A1 (en) 2007-12-19 2009-07-09 Smith Kline Beecham Corporation Prolyl hydroxylase inhibitors
US20110003013A1 (en) 2008-01-04 2011-01-06 Garvan Institute Of Medical Research Method of increasing metabolism
WO2009089547A1 (en) 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
CA2712583A1 (en) 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydrothieno pyridines
US8372863B2 (en) 2008-02-25 2013-02-12 Merck Sharp & Dohme Corp. Tetrahydro-1H-pyrrolo fused pyridones
WO2009108496A1 (en) 2008-02-25 2009-09-03 Merck & Co., Inc. Tetrahydrofuropyridones
AU2009225869B2 (en) 2008-03-18 2014-01-23 Merck Sharp & Dohme Llc Substituted 4-hydroxypyrimidine-5-carboxamides
EP2294066B9 (en) * 2008-04-28 2015-03-11 Janssen Pharmaceutica, N.V. Benzoimidazoles as prolyl hydroxylase inhibitors
WO2010093727A1 (en) 2009-02-10 2010-08-19 Janssen Pharmaceutica Nv Quinazolinones as prolyl hydroxylase inhibitors
WO2012021830A1 (en) 2010-08-13 2012-02-16 Janssen Pharmaceutica Nv 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors
ES2689481T3 (en) * 2011-10-25 2018-11-14 Janssen Pharmaceutica Nv Formulations of 1- (5,6-dichloro-1h-benzo [d] imidazol-2-yl) -1h-pyrazol-4-carboxylic acid meglumine salt

Also Published As

Publication number Publication date
JP2017141270A (en) 2017-08-17
CN106038556A (en) 2016-10-26
US9273034B2 (en) 2016-03-01
AU2017204598B2 (en) 2019-03-28
CA2853455C (en) 2019-12-03
CY1123426T1 (en) 2021-12-31
EP3461820A1 (en) 2019-04-03
NZ624022A (en) 2015-05-29
US20140329873A1 (en) 2014-11-06
US9708298B2 (en) 2017-07-18
HUE052128T2 (en) 2021-04-28
EP3461820B1 (en) 2020-07-29
US20160340338A1 (en) 2016-11-24
EP2776023B1 (en) 2016-03-09
WO2013063221A1 (en) 2013-05-02
ES2574262T3 (en) 2016-06-16
MX344109B (en) 2016-12-05
EP3091009A1 (en) 2016-11-09
KR102087020B1 (en) 2020-03-11
US10807969B2 (en) 2020-10-20
AU2012328763A1 (en) 2014-05-01
BR112014009910B1 (en) 2020-06-30
BR112014009910A2 (en) 2017-04-25
CA2853455A1 (en) 2013-05-02
EP2776023A1 (en) 2014-09-17
ES2818977T3 (en) 2021-04-14
ES2689481T3 (en) 2018-11-14
US20180201605A1 (en) 2018-07-19
HK1202237A1 (en) 2015-09-25
MX368157B (en) 2019-09-20
CN104053439B (en) 2016-08-24
US20190152955A1 (en) 2019-05-23
CN104053439A (en) 2014-09-17
MX2014005075A (en) 2014-08-08
AU2017204598A1 (en) 2017-07-27
KR20140094547A (en) 2014-07-30
JP6122862B2 (en) 2017-04-26
JP2014530915A (en) 2014-11-20
EP3091009B1 (en) 2018-08-29

Similar Documents

Publication Publication Date Title
IN2014DN03155A (en)
MX2010007714A (en) Fused pyridines active as inhibitors of c-met.
MY180666A (en) Substituted pyrazolo [3,4-b] pyridines as medicaments
WO2010093727A8 (en) Quinazolinones as prolyl hydroxylase inhibitors
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
WO2017132432A8 (en) Benzimidazole derivatives as modulators of ror-gamma
UA110310C2 (en) Compounds n-aryl triazole as antagonists receptors lisophosphatidic acid (lpar)
NZ630719A (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
MX2010010647A (en) Process for preparing orally administered dabigatran formulations.
UA109868C2 (en) N -alkyltriazole compounds asr
PH12012502569A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
UA112425C2 (en) SUBSTITUTED N- (1H-INDASOL-4-IL) IMIDASO [1,2-a] PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RECIPE TYROSININAS III TYPININASE
MX2014000341A (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease.
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
UA99141C2 (en) Substituted indazole derivatives active as kinase inhibitors
WO2009091374A3 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
UA107952C2 (en) Derivatives of imidazo [1,2-a] pyrazine and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases
EA201171306A1 (en) SUBSTITUTED IMIDAZO [1,2-α] PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE AS β-SECRETASE INHIBITORS
CR20200286A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
WO2011051490A3 (en) Heterocyclic derivatives
WO2014070991A3 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors
WO2014141035A3 (en) Fused heterocyclyl derivatives as nampt inhibitors
WO2014072930A3 (en) Fused pyridine derivatives as antibacterial agents